The economic and clinical burden of early versus late initiation of celecoxib among patients with osteoarthritis

The economic and clinical burden of early versus late initiation of celecoxib among patients with osteoarthritis

Ahmed Shelbaya,1,2 Caitlyn T Solem,3 Chris Walker,4 Yin Wan,3 Courtney Johnson,3 Joseph C Cappelleri1 1Pfizer Inc., New York, NY, 2Columbia School of Public Health, New York, NY, 3Pharmerit International, Bethesda, MD, USA; 4Pfizer Ltd., Tadworth, Surrey, UK Objective: This study aimed to evaluate t...

Full description

Bibliographic Details
Main Authors: Shelbaya A, Solem CT, Walker C, Wan Y, Johnson C, Cappelleri JC
Format: Article
Language:English
Published: Dove Medical Press 2018-04-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
osteoarthritis
celecoxib
nonsteroidal anti-inflammatory drug
economic burden
healthcare resource use
Online Access:https://www.dovepress.com/the-economic-and-clinical-burden-of-early-versus-late-initiation-of-ce-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/the-economic-and-clinical-burden-of-early-versus-late-initiation-of-ce-peer-reviewed-article-CEOR

Similar Items